377 related articles for article (PubMed ID: 21323909)
1. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
[TBL] [Abstract][Full Text] [Related]
2. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
[TBL] [Abstract][Full Text] [Related]
5. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson's Disease.
Burgaz S; García C; Gómez-Cañas M; Rolland A; Muñoz E; Fernández-Ruiz J
Molecules; 2021 May; 26(11):. PubMed ID: 34071302
[TBL] [Abstract][Full Text] [Related]
8. Pure Δ
Romano B; Pagano E; Orlando P; Capasso R; Cascio MG; Pertwee R; Marzo VD; Izzo AA; Borrelli F
Pharmacol Res; 2016 Nov; 113(Pt A):199-208. PubMed ID: 27498155
[TBL] [Abstract][Full Text] [Related]
9. Similarities and differences upon binding of naturally occurring Δ
Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
[TBL] [Abstract][Full Text] [Related]
10. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
12. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
13. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
Bolognini D; Costa B; Maione S; Comelli F; Marini P; Di Marzo V; Parolaro D; Ross RA; Gauson LA; Cascio MG; Pertwee RG
Br J Pharmacol; 2010 Jun; 160(3):677-87. PubMed ID: 20590571
[TBL] [Abstract][Full Text] [Related]
14. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.
Walsh S; Mnich K; Mackie K; Gorman AM; Finn DP; Dowd E
Brain Res Bull; 2010 Apr; 81(6):543-8. PubMed ID: 20097273
[TBL] [Abstract][Full Text] [Related]
15. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Gilgun-Sherki Y; Melamed E; Mechoulam R; Offen D
Pharmacol Toxicol; 2003 Aug; 93(2):66-70. PubMed ID: 12899667
[TBL] [Abstract][Full Text] [Related]
16. Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors.
Bátkai S; Mukhopadhyay P; Horváth B; Rajesh M; Gao RY; Mahadevan A; Amere M; Battista N; Lichtman AH; Gauson LA; Maccarrone M; Pertwee RG; Pacher P
Br J Pharmacol; 2012 Apr; 165(8):2450-61. PubMed ID: 21470208
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of the phytocannabinoid Δ
Espadas I; Keifman E; Palomo-Garo C; Burgaz S; García C; Fernández-Ruiz J; Moratalla R
Neurobiol Dis; 2020 Jul; 141():104892. PubMed ID: 32387338
[TBL] [Abstract][Full Text] [Related]
18. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
Concannon RM; Okine BN; Finn DP; Dowd E
Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
[TBL] [Abstract][Full Text] [Related]
19. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Yan J; Xu Y; Zhu C; Zhang L; Wu A; Yang Y; Xiong Z; Deng C; Huang XF; Yenari MA; Yang YG; Ying W; Wang Q
PLoS One; 2011; 6(6):e20945. PubMed ID: 21731633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
